1 documents found
Registration Number

0221U101265, 0120U103333 , R & D reports

Title

Development of cardiomyogenic fibroblast reprogramming technology using CRISPR-Cas9 system as a potential method of improving heart function after heart attack

popup.stage_title

Head

Piven Oksana O., Кандидат біологічних наук

Registration Date

18-01-2021

Organization

Institute of Molecular Biology and Genetics of NAS of Ukraine

popup.description2

 During the year, bioinformatics analysis of promoter regions of human cardiogenesis genes was performed: GATA4, MEF2C, TBX5, HAND2 MYOD1. Designs of promising gRNAs for activation of human cardiogenesis genes by CRISPR-VPR system have been developed. All sequences were synthesized and cloned into a plasmid for Cas9sgRNA expression (Addgene # 68463). A plasmid expressing fusion proteins of catalytically inactivated Cas9 and transcription activation domains - VPR was also developed. Therefore, a collection of plasmids expressing selected gRNA sequences was created for further molecular genetic analysis and in vitro validation. In general, the data obtained by us are a necessary and logical basis for studying the prospects of using the CRISPR system for cell reprogramming for therapeutic purposes.

Product Description

popup.authors

Macewicz Larysa L
Ruban Tetiana P
Sklyarenko Yuliya V

R & D report
Development of cardiomyogenic fibroblast reprogramming technology using CRISPR-Cas9 system as a potential method of improving heart function after heart attack
Head: Piven Oksana O.. Development of cardiomyogenic fibroblast reprogramming technology using CRISPR-Cas9 system as a potential method of improving heart function after heart attack. (popup.stage: ). Institute of Molecular Biology and Genetics of NAS of Ukraine. № 0221U101265
1 documents found

Updated: 2024-12-22


Роздрукувати цю сторінку